Whistleblower says he was ousted after raising concerns about malaria drug

and one of the reasons it's President Trump's favorite drug combination to talk about. I just hope that hydroxy Clara Quinn winds, coupled with perhaps the CPAC, is we call it. But Tuesday, the National Institutes of Health recommended against the combination of hydroxy claure Quinn. And is it through Myson and Antibiotic, also sold as a Z pack unless a patient is in a clinical trial, saying there is potential for toxicities. At the White House briefing Tuesday evening, a panel of experts in the N. I H is actually now recommending against the use hydroxy chlor equate in combination with Z pack, which is something you okay? Always willing to take a look. There are several other drugs being studied to see if they'll help Cove in 19 patients, such as the antiviral drug Rendez Severe. The N I H panel didn't endorse any of them, saying more clinical trials need to be done. And now doctors were planning to study another class of drugs those that treat blood clots. Virtually every single person that I'm seeing that I'm asked to interview and examine has a clotting problem with Coke. Severe Kobe disease and the clotting problems aren't the most profound that I've ever seen. And the I C U setting. Broadway actor Nick Cordero contracted the novel Corona Virus and had his leg amputated because of a blood clot. He survived. But blood clots can be deadly. Doctors trying to figure out the right drug to prevent thes clots, another way to save the lives of patients with the novel Corona virus.

A government scientist was ousted after the Trump administration ignored his dire warnings about COVID-19 and a malaria drug President Donald Trump was pushing for the coronavirus despite scant evidence it helped, according to a whistleblower complaint Tuesday.Rick Bright, former director of the Biomedical Advanced Research and Development Authority, filed the complaint Tuesday with the Office of Special Counsel, a government agency responsible for whistleblower complaints.He alleges he was reassigned to a lesser role because he resisted political pressure to allow widespread use of hydroxychloroquine, a malaria drug favored by Trump. He said the Trump administration wanted to “flood” hot spots in New York and New Jersey with the drug.Bright also said the Trump administration rejected his warnings on COVID-19, the disease caused by the virus. He said he “acted with urgency” to address the growing spread of COVID-19 after the World Health Organization issued a warning in January.He said he “encountered resistance from HHS leadership, including Health and Human Services Secretary (Alex) Azar, who appeared intent on downplaying this catastrophic event.”Video above: Despite FDA warnings, President Trump touts malaria drugBright alleges in the complaint that political appointees at the Department of Health and Human Services had tried to promote hydroxychloroquine “as a panacea.” The officials also “demanded that New York and New Jersey be ‘flooded’ with these drugs, which were imported from factories in Pakistan and India that had not been inspected by the FDA,” the complaint says.But Bright opposed broad use of the drug, arguing the scientific evidence wasn’t there to back up its use in coronavirus patients. He felt an urgent need to tell the public that there wasn’t enough scientific evidence to support using the drugs for COVID-19 patients, the complaint states.Last month, the U.S. Food and Drug Administration warned doctors against prescribing the drug except in hospitals and research studies. In an alert, regulators flagged reports of sometimes fatal heart side effects among coronavirus patients taking hydroxychloroquine or the related drug chloroquine.The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause a number of side effects, including heart rhythm problems, severely low blood pressure and muscle or nerve damage.The complaint said officials had “refused to listen or take appropriate action to accurately inform the public.”Bright said he had to tell the public about the lack of science backing up its use, despite the drug being pushed by the president as press briefings, “to protect it from drugs which he believed constituted a substantial and specific danger to public health and safety,” the complaint says.“As the death toll mounted exponentially each day, Dr. Bright concluded that he had a moral obligation to the American public, including those vulnerable as a result of illness from COVID-19, to protect it from drugs which he believed constituted a substantial and specific danger to public health and safety,” the complaint says.On Jan. 20, according to the complaint, the WHO held an emergency call to discuss the novel coronavirus. It was attended by many HHS officials, and which WHO officials advised that “the outbreak is a big problem.”Trump has accused the U.N. agency of mismanaging and covering up the spread of the virus after it emerged in China and said he would cut funding.In the complaint, Bright says he wants a full investigation and to be returned to his position as the director.A spokeswoman for HHS has said it was Bright who had requested an emergency use authorization for chloroquine and hydroxychloroquine. For his part, Bright said he had insisted that the authorization be limited to a restricted group of patients — those hospitalized with confirmed COVID-19 under the supervision of a doctor.

WASHINGTON —

A government scientist was ousted after the Trump administration ignored his dire warnings about COVID-19 and a malaria drug President Donald Trump was pushing for the despite scant evidence it helped, according to a whistleblower complaint Tuesday.

Rick Bright, former director of the Biomedical Advanced Research and Development Authority, filed the complaint Tuesday with the Office of Special Counsel, a government agency responsible for whistleblower complaints.

He alleges he was reassigned to a lesser role because he resisted political pressure to allow widespread use of , a malaria drug favored by Trump. He said the Trump administration wanted to “flood” hot spots in New York and New Jersey with the drug.

Bright also said the Trump administration rejected his warnings on COVID-19, the disease caused by the virus. He said he “acted with urgency” to address the growing spread of COVID-19 after the World Health Organization issued a warning in January.

He said he “encountered resistance from HHS leadership, including Health and Human Services Secretary (Alex) Azar, who appeared intent on downplaying this catastrophic event.”

Video above: Despite FDA warnings, President Trump touts malaria drug

Bright alleges in the complaint that political appointees at the Department of Health and Human Services had tried to promote hydroxychloroquine “as a panacea.” The officials also “demanded that New York and New Jersey be ‘flooded’ with these drugs, which were imported from factories in Pakistan and India that had not been inspected by the FDA,” the complaint says.

But Bright opposed broad use of the drug, arguing the scientific evidence wasn’t there to back up its use in coronavirus patients. He felt an urgent need to tell the public that there wasn’t enough scientific evidence to support using the drugs for COVID-19 patients, the complaint states.

Last month, the except in hospitals and research studies. In an alert, regulators flagged reports of sometimes fatal heart side effects among coronavirus patients taking hydroxychloroquine or the related drug chloroquine.

The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause a number of side effects, including heart rhythm problems, severely low blood pressure and muscle or nerve damage.

The complaint said officials had “refused to listen or take appropriate action to accurately inform the public.”

Bright said he had to tell the public about the lack of science backing up its use, despite the drug being pushed by the president as press briefings, “to protect it from drugs which he believed constituted a substantial and specific danger to public health and safety,” the complaint says.

“As the death toll mounted exponentially each day, Dr. Bright concluded that he had a moral obligation to the American public, including those vulnerable as a result of illness from COVID-19, to protect it from drugs which he believed constituted a substantial and specific danger to public health and safety,” the complaint says.

On Jan. 20, according to the complaint, the WHO held an emergency call to discuss the novel coronavirus. It was attended by many HHS officials, and which WHO officials advised that “the outbreak is a big problem.”

Trump has accused the U.N. agency of mismanaging and covering up the spread of the virus after it emerged in China and said he would cut funding.

In the complaint, Bright says he wants a full investigation and to be returned to his position as the director.

A spokeswoman for HHS has said it was Bright who had requested an emergency use authorization for chloroquine and hydroxychloroquine. For his part, Bright said he had insisted that the authorization be limited to a restricted group of patients — those hospitalized with confirmed COVID-19 under the supervision of a doctor.

��vlog